July 23, 2016 1:31 PM ET


Company Overview of E. Merck KG

Company Overview

E. Merck KG operates as a general partner for Merck KGaA, which develops, manufactures, and distributes pharmaceutical products. The company is based in Darmstadt, Germany.

Frankfurter Strasse 250

Darmstadt,  64293


Key Executives for E. Merck KG

Chairman of the Executive Board of Merck KGaA and Chief Executive Officer at Merck KGaA
Age: 59
Member of executive Board
Age: 65
Compensation as of Fiscal Year 2016.

E. Merck KG Key Developments

E. Merck KG Announces Board Appointments, Effective April 30, 2016

E. Merck KG has named Udit Batra, currently head of the life science business sector, and Walter Galinat, currently head of the performance materials business sector, as new members to its executive board, effective April 30, 2016. Bernd Reckmann, currently the Executive Board member responsible for Life Science and Performance Materials, will retire on conclusion of the Annual General Meeting on April 29, 2016. Prior to joining Merck KGaA, Darmstadt, Germany, Batra worked for Novartis as Head of Global Public Health and Market Access for Vaccines and Diagnostics, as Global Head of Corporate Strategy, and as Country President of the pharmaceutical business in Australia.

E. Merck KG, Annual General Meeting, Apr 29, 2016

E. Merck KG, Annual General Meeting, Apr 29, 2016. Agenda: To approve executive changes.

E. Merck KG Announces Management Changes, Effective January 1, 2015

Merck KGaA announced E. Merck KG has appointed Stefan Oschmann to the position of Vice Chairman and Deputy CEO. Concurrently, Bel n Garijo has been appointed to the Executive Board to take over leadership for the Pharma business. The management changes will be effective as of January 1, 2015. Oschmann, currently CEO Pharma, will represent Karl-Ludwig Kley, Chief Executive Officer and Chairman of the Executive Board, in hisresponsibilities. Both will share strategic management functions and represent the company with politicians and international organizations. As a member of the Executive Board, Garijo, currently CEO of Merck's biopharmaceutical division Merck Serono, will assume responsibility for the whole Pharma business, which in addition to Merck Serono comprisesConsumer Health, Allergy and Biosimilars.

Similar Private Companies By Industry

Company Name Region
3B Pharmaceuticals GmbH Europe
Accelsiors Group International Europe
Aenova Group GmbH Europe
Aenova Holding GmbH Europe
AiCuris GmbH & Co. KG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact E. Merck KG, please visit www.merckgroup.com/en/company/management/e_merck_kg/e_merck_kg.html. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.